The “Cicada” COVID Variant: What You Need to Know About the Highly Mutated BA.3.2 Strain
New Delhi, March 27, 2026 — Just as the world has settled into a post-pandemic normal, a newly identified COVID-19 variant with an unusually high number of mutations is drawing the attention of global health authorities. Officially designated as BA.3.2, the strain has been informally dubbed the “Cicada” variant. It is currently spreading across several states in the US, prompting infectious disease experts to renew calls for genomic surveillance.
Here is a quick breakdown of what the Cicada variant is, its symptoms, and what it means for global health.
Why is it called the “Cicada” Variant?
The nickname “Cicada” was coined by evolutionary biologists due to the virus’s peculiar evolutionary pattern. Much like the cicada insect, which spends years dormant underground before suddenly emerging, the BA.3.2 variant stayed largely under the radar for an extended period.
It is a descendant of the older Omicron BA.3 lineage, which had essentially disappeared from global circulation years ago. It circulated quietly without triggering major alarms before recently resurfacing with significant genetic alterations.
A Highly Mutated Profile
What sets the Cicada variant apart from recently dominant strains is its sheer volume of genetic changes. BA.3.2 carries over 70 mutations, many of which are on the spike protein.
Because of this heavily mutated profile, experts warn that Cicada possesses strong “immune escape” characteristics. This means the virus is highly efficient at partially bypassing the antibodies generated by older vaccines or previous COVID-19 infections. However, health officials emphasize that while the variant is contagious, there is currently no evidence to suggest that it causes more severe disease or leads to higher hospitalization rates.
Symptoms and US Spread
The symptoms of the BA.3.2 variant largely mirror those of other recent COVID-19 strains, though physicians have noted a few distinct trends. The most commonly reported symptoms include:
Severe sore throat
Congestion and runny nose
Fever or chills
Persistent cough
Fatigue and headaches
Gastrointestinal issues (such as nausea or diarrhea)
As of late March 2026, the Cicada variant has been detected in wastewater samples and clinical tests across multiple US states.
Should India Be Worried?
With the variant spreading in the US, questions are naturally arising about its potential impact on India. Currently, Indian health authorities are maintaining a watchful eye, emphasizing that there is no need for panic.
Experts suggest that while localized surges are always possible due to international travel, India’s broad hybrid immunity (from both vaccines and widespread previous infections) continues to offer a strong buffer against severe illness. Furthermore, existing vaccines remain highly effective at preventing severe complications and hospitalization, even if they don’t completely stop transmission.
The World Health Organization (WHO) is actively monitoring the situation, but the current consensus is clear: stay vigilant, practice basic hygiene, and there is no immediate cause for alarm.
